TY - JOUR
T1 - Design and pilot results from the Million Veteran Program Return Of Actionable Results (MVP-ROAR) Study
AU - Million Veteran Program
AU - Vassy, Jason L.
AU - Brunette, Charles A.
AU - Yi, Thomas
AU - Harrison, Alicia
AU - Cardellino, Mark P.
AU - Assimes, Themistocles L.
AU - Christensen, Kurt D.
AU - Devineni, Poornima
AU - Gaziano, J. Michael
AU - Gong, Xin
AU - Hui, Qin
AU - Knowles, Joshua W.
AU - Muralidhar, Sumitra
AU - Natarajan, Pradeep
AU - Pyarajan, Saiju
AU - Sears, Mary Gavin
AU - Shi, Yunling
AU - Sturm, Amy C.
AU - Whitbourne, Stacey B.
AU - Sun, Yan V.
AU - Danowski, Morgan E.
N1 - Publisher Copyright:
© 2024
PY - 2024/10
Y1 - 2024/10
N2 - Background: As a mega-biobank linked to a national healthcare system, the Million Veteran Program (MVP) can directly improve the health care of participants. To determine the feasibility and outcomes of returning medically actionable genetic results to MVP participants, the program launched the MVP Return of Actionable Results (MVP-ROAR) Study, with familial hypercholesterolemia (FH) as an exemplar actionable condition. Methods: The MVP-ROAR Study consists of a completed single-arm pilot phase and an ongoing randomized clinical trial (RCT), in which MVP participants are recontacted and invited to receive clinical confirmatory gene sequencing testing and a telegenetic counseling intervention. The primary outcome of the RCT is 6-month change in low-density lipoprotein cholesterol (LDL-C) between participants receiving results at baseline and those receiving results after 6 months. Results: The pilot developed processes to identify and recontact participants nationally with probable pathogenic variants in low-density lipoprotein receptor (LDLR) on the MVP genotype array, invite them to clinical confirmatory gene sequencing, and deliver a telegenetic counseling intervention. Among participants in the pilot phase, 8 (100%) had active statin prescriptions after 6 months. Results were shared with 16 first-degree family members. Six-month ΔLDL-C (low-density lipoprotein cholesterol) after the genetic counseling intervention was −37 mg/dL (95% CI: −12 to −61; P = .03). The ongoing RCT will determine between-arm differences in this primary outcome. Conclusion: While underscoring the importance of clinical confirmation of research results, the pilot phase of the MVP-ROAR Study marks a turning point in MVP and demonstrates the feasibility of returning genetic results to participants and their providers. The ongoing RCT will contribute to understanding how such a program might improve patient health care and outcomes. Clinical Trial Registration: ClinicalTrials.gov ID NCT04178122.
AB - Background: As a mega-biobank linked to a national healthcare system, the Million Veteran Program (MVP) can directly improve the health care of participants. To determine the feasibility and outcomes of returning medically actionable genetic results to MVP participants, the program launched the MVP Return of Actionable Results (MVP-ROAR) Study, with familial hypercholesterolemia (FH) as an exemplar actionable condition. Methods: The MVP-ROAR Study consists of a completed single-arm pilot phase and an ongoing randomized clinical trial (RCT), in which MVP participants are recontacted and invited to receive clinical confirmatory gene sequencing testing and a telegenetic counseling intervention. The primary outcome of the RCT is 6-month change in low-density lipoprotein cholesterol (LDL-C) between participants receiving results at baseline and those receiving results after 6 months. Results: The pilot developed processes to identify and recontact participants nationally with probable pathogenic variants in low-density lipoprotein receptor (LDLR) on the MVP genotype array, invite them to clinical confirmatory gene sequencing, and deliver a telegenetic counseling intervention. Among participants in the pilot phase, 8 (100%) had active statin prescriptions after 6 months. Results were shared with 16 first-degree family members. Six-month ΔLDL-C (low-density lipoprotein cholesterol) after the genetic counseling intervention was −37 mg/dL (95% CI: −12 to −61; P = .03). The ongoing RCT will determine between-arm differences in this primary outcome. Conclusion: While underscoring the importance of clinical confirmation of research results, the pilot phase of the MVP-ROAR Study marks a turning point in MVP and demonstrates the feasibility of returning genetic results to participants and their providers. The ongoing RCT will contribute to understanding how such a program might improve patient health care and outcomes. Clinical Trial Registration: ClinicalTrials.gov ID NCT04178122.
UR - https://www.scopus.com/pages/publications/85200941951
U2 - 10.1016/j.ahj.2024.04.021
DO - 10.1016/j.ahj.2024.04.021
M3 - Article
C2 - 38762090
AN - SCOPUS:85200941951
SN - 0002-8703
VL - 276
SP - 99
EP - 109
JO - American Heart Journal
JF - American Heart Journal
ER -